


## Sitaxsentan

## Chemical Properties

CAS No. :	184036-34-8
Formula:	C <sub>18</sub> H <sub>15</sub> ClN <sub>2</sub> O <sub>6</sub> S <sub>2</sub>
Molecular Weight:	454.9
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Sitaxsentan (TBC-11251) is A selective endothelin A (ETA) receptor antagonist. Endothelin is an effective vasoconstrictor. Sitaxsentan blocks the binding of endothelin to its receptors, thereby eliminating the harmful effects of endothelin.
Targets(IC50)	Endothelin Receptor

## Solubility Information

Solubility	DMSO: 4.55 mg/mL (10 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1983 mL	10.9914 mL	21.9829 mL
5 mM	0.4397 mL	2.1983 mL	4.3966 mL
10 mM	0.2198 mL	1.0991 mL	2.1983 mL
50 mM	0.044 mL	0.2198 mL	0.4397 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Marcus Chin, et al. Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy. *Can Respir J*. 2012 Jan-Feb;19(1):e1-2.

Sandoval J, et al. STRIDE-4 investigators. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. *Pulm Pharmacol Ther*. 2012 Feb;25(1):33-9. Epub 2011 Nov 2.

Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. *Vasc Health Risk Manag*. 2011;7:119-24. Epub 2011 Mar 2.

Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension. *Am J Physiol Heart Circ Physiol*. 2010 Oct;299(4):H1118-23. Epub 2010 Aug 6.

Kaehler, et al. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxsentan. *Wien Klin Wochenschr*. 2011 Apr;123(7-8):248-52. Epub 2011 Mar 31.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481